Fredun Pharmaceuticals P/E Ratio
Fredun Pharmaceuticals (FREDUN) P/E ratio is 53.34 (High), EPS (TTM) ₹66.81, current price ₹1303.50 on NSE vs historical average P/E of 22.8 (100.0th percentile) — Very High - High growth expectations or significantly overvalued.
Current Valuation Metrics
Valuation Signal
Sector Context
Earnings Breakdown (TTM)
FREDUN P/E Ratio — Valuation Signal & Historical Context
Fredun Pharmaceuticals P/E 53.34 vs historical average 22.8, range 22.8–22.8 — signal: Overvalued. Also explore FREDUN stock price history to track price trends across different timeframes.
- Stock appears overvalued with PE of 53.34, suggesting caution for new investments
- Current PE is 133.9% above historical average
Fredun Pharmaceuticals P/E Ratio Historical Trend
FREDUN annual price-to-earnings ratio — 1 years, EPS and year-end price. Current P/E 53.34 vs historical average 22.8. For live price, revenue and the complete fundamental profile, see FREDUN share price.
FREDUN Historical P/E Ratio — EPS, Year-End Price & Valuation
Fredun Pharmaceuticals annual P/E ratio, EPS (₹), year-end price and valuation category on NSE.
| Year | P/E Ratio | EPS (₹) | Year-end Price (₹) | Exchange | Valuation |
|---|---|---|---|---|---|
| 2025 | 22.8 | 69.21 | ₹1578.30 | BSE | Moderate |
FREDUN vs Healthcare Peers — P/E Ratio Comparison
Fredun Pharmaceuticals P/E 53.34 vs Healthcare average 56.76, median 31.66 — range 1.99–747.21.
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Sunrest Lifescience | SUNREST | 1.99 | ₹66 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Colinz Laboratories | COLINZ | 3.27 | ₹9 | Low |
| Phaarmasia | PHRMASI | 3.41 | ₹59 | Low |
| Sun Pharma Advanced Rese… | SPARC | 4.03 | ₹6,361 | Low |
| Dipna Pharmachem | DPL | 4.65 | ₹12 | Low |
| JFL Life Sciences | JFLLIFE | 4.95 | ₹67 | Low |
| Shelter Pharma | SHELTER | 5.71 | ₹56 | Low |
| GKB Ophthalmics | GKB | 5.9 | ₹33 | Low |
| Kabra Drugs | KABRADG | 6.29 | ₹49 | Low |